Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01

Jacob Sands, MD, provides a post hoc analysis of TROPION-Lung01 , which showed improved intracranial activity and progression-free survival with datopotamab deruxtecan (Dato-DXd) versus docetaxel. Among patients with measurable brain metastases, Dato-DXd achieved a central nervous system confirmed overall response rate of 38%, with all evaluable patients showing disease control. No intracranial responses were seen in the docetaxel arm.